The rheological properties of blood play a significant role in the onset and progression of arterial hypertension. The aim of our work was to evaluate the effect of the angiotensin-converting enzyme inhibitor captopril (20 mg/kg/d), pentoxifylline (PTX; 100 mg/kg/d), and the combination of captopril + PTX (20 + 100 mg/kg/d) on the hemodynamic and hemorheological parameters in spontaneously hypertensive rats (SHRs) during the development of arterial hypertension. In the group of animals that received captopril, the mean arterial pressure (MAP) was significantly lower by 30% due to a decrease in cardiac output of 23% and in total peripheral resistance (TPR) of 26% compared with the control group, whereas blood viscosity did not change significantly. PTX-treated SHRs had significantly lower MAP and TPR (by 19% and 31%, respectively) and blood viscosity (by 4%-6%) and a higher erythrocyte deformability index (by 1.5%-2%) than the control group. In the group of animals that received captopril + PTX, MAP and TPR were significantly lower, by 41% and 46%, than those in the control group, and by 16% and 27% than those in the captopril group. The combination of the angiotensin-converting enzyme inhibitor captopril and the hemorheological agent PTX, affecting various systems that are involved in blood pressure regulation, exhibits synergism and prevents an increase in arterial blood pressure during the development of arterial hypertension in SHRs (ie, from 5 to 11 weeks of life).

中文翻译：

---

己酮可可碱治疗通过在动脉高血压发展过程中自发性高血压大鼠的血液流变学改善来增强卡托普利的降压活性。

血液的流变特性在动脉高血压的发作和发展中起重要作用。我们的工作目的是评估血管紧张素转换酶抑制剂卡托普利（20 mg / kg / d），己酮可可碱（PTX; 100 mg / kg / d）以及卡托普利+ PTX的组合（20 + 100）的作用（mg / kg / d）对自发性高血压大鼠（SHRs）在动脉高压发展过程中的血流动力学和血液流变学参数的影响。与对照组相比，接受卡托普利的动物组的平均动脉压（MAP）显着降低了30％，这是因为心输出量降低了23％，总外周阻力（TPR）降低了26％。血液粘度没有明显改变。经PTX处理的​​SHRs的MAP和TPR明显降低（分别降低了19％和31％，血液粘度（分别为4％-6％）和更高的红细胞变形指数（分别为1.5％-2％）。在接受卡托普利+ PTX的动物组中，MAP和TPR分别比对照组低41％和46％，比卡托普利组低16％和27％。血管紧张素转换酶抑制剂卡托普利和血液流变剂PTX的组合会影响参与血压调节的各种系统，在SHRs发生高血压的过程中表现出协同作用并防止动脉血压升高（即从5开始到11周的生命）。分别比对照组高41％和46％，比卡托普利组高16％和27％。血管紧张素转换酶抑制剂卡托普利和血液流变剂PTX的组合会影响参与血压调节的各种系统，在SHR发生高血压时，会表现出协同作用并防止动脉血压升高（即从5开始到11周的生命）。分别比对照组高41％和46％，比卡托普利组高16％和27％。血管紧张素转换酶抑制剂卡托普利和血液流变剂PTX的组合会影响参与血压调节的各种系统，在SHR发生高血压时，会表现出协同作用并防止动脉血压升高（即从5开始到11周的生命）。